Product Description: Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Martin Hutchings, et al. CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam. Blood (2022) 140 (Supplement 1): 10733-10735.